CrowdStrike and Vertex Pharmaceuticals: Financial experts predict top performance in 2024.

CrowdStrike and Vertex Pharmaceuticals: Financial experts predict top performance in 2024.

According to a report by www.aktienwelt360.de,

As 2023 comes to a close, shares of CrowdStrike and Vertex Pharmaceuticals have seen significant gains. It is predicted that the two companies' strong year on the stock market could be repeated in 2024. It is recommended to at least keep the stocks of these companies on the watchlist in the coming year.

CrowdStrike, as a leading cybersecurity company, is benefiting from a booming market. With its cloud-native platform based on artificial intelligence, the company was able to significantly increase its sales and annual recurring revenue. With a total addressable market in 2028 of $225 billion, growth could continue for a long time. CrowdStrike stock was trading at a 2024 P/E ratio of 87 on the back of its monster rally in 2023, but the company's huge growth potential must be taken into account.

Vertex Pharmaceuticals, the only company in the world with a treatment for cystic fibrosis, recently reached an important milestone in reducing its dependence on the disease. The company, together with its partner CRISPR Therapeutics, has received approval for a gene therapy and also has an acute pain treatment in the pipeline. Vertex Pharmaceuticals stock trades at a 2024 P/E of 27, and the elevated valuation may well be justified considering its monopoly position in cystic fibrosis and its promising pipeline.

The performance of these stocks is therefore of great interest to investors. The 2024 forecasts suggest that investors should continue to monitor these stocks to avoid missing out on potential opportunities.